Plexus Corp. Form 10-K Summary
Business context and reporting period. Plexus provides design, supply-chain, manufacturing and lifecycle services for complex, regulated products in Healthcare/Life Sciences, Industrial and Aerospace/Defense. This annual report covers the fiscal year ended September 30, 2023 (52 weeks). Although the request references 2023 Q4, the filing does not provide a clear standalone fourth-quarter income statement or cash-flow summary.
Key financial metrics
| Metric | FY2023 | FY2022 |
|---|---|---|
| Net sales | $4,210.3 million | $3,811.4 million |
| Gross profit / margin | $394.6 million / 9.4% | $347.2 million / 9.1% |
| Operating income / margin | $195.8 million / 4.7% | $178.2 million / 4.7% |
| Net income | $139.1 million | $138.2 million |
| Diluted EPS | $4.95 | $4.86 |
| Operating cash flow | $165.8 million | $(26.2) million |
| Free cash flow (non-GAAP) | $61.8 million | $(127.9) million |
At September 30, 2023, cash and restricted cash were $256.7 million; total debt, finance lease and other financing obligations were $431.1 million. Revolver borrowings were $233 million, leaving $267 million available under the $500 million facility. Current assets were $2.67 billion and current liabilities $1.81 billion. Inventory was $1.56 billion, and annualized cash-cycle days increased to 87 from 73.
Material changes versus prior year
- Sales grew 10.5%. Healthcare/Life Sciences increased 19.7%, Aerospace/Defense 17.5%, and Industrial was nearly flat, up 0.2%.
- Gross margin improved 30 basis points to 9.4%, while operating margin remained 4.7%.
- Net income edged up 0.7%; higher operating income was largely offset by higher interest and other expense and income tax expense. Interest expense rose to $31.5 million from $15.9 million.
- Operating cash flow improved substantially, principally as inventory and receivables uses of cash eased compared with FY2022. Cash declined by $18.8 million during FY2023.
- ROIC, a non-GAAP measure, increased to 13.4% from 13.0%; management’s long-term target is 15%.
Outlook, management commentary and risks
- Management expects FY2024 capital expenditures of approximately $100–$120 million, excluding site expansions, and an effective tax rate of approximately 14%–16%, assuming no tax-law changes. No specific revenue or earnings guidance is provided in the filing.
- The company’s long-term financial model targets 9%–12% compounded annual revenue growth and 15% ROIC. Management says cash, expected operating cash flows and available credit should meet liquidity needs for the next 12 months.
- Supply constraints and long component lead times have required significant inventory investment. Inflation in components, labor and operating costs has been partly recovered through customer pricing, but those recoveries may dilute margins. China-related export controls have caused forecast volatility for some customers.
- Customer concentration remains material: the top 10 customers represented 49.6% of sales, and GE Healthcare Technologies represented 10.3%. APAC accounted for the largest share of sales; operations and cash are concentrated in Malaysia and other locations outside the U.S.
- A one-time Norway arbitration matter resulted in a $15.8 million cash payment and a $14.2 million charge, net of insurance recoveries and prior accruals. Plexus no longer serves that customer, expects no further charges and is pursuing insurance recoveries.
- Management expects global minimum-tax rules to unfavorably affect tax holidays and the effective tax rate, with impacts anticipated to begin in FY2025 and increase in FY2026.
- Other material risks include customers changing or canceling orders, excess or obsolete inventory, component quality and availability, labor costs and staffing, cybersecurity, regulatory compliance, geopolitical and currency risks, and potential increases in variable-rate borrowing costs.
Important facts for investors to verify
- Review subsequent results for whether inventory, cash-cycle days and working-capital cash flows improve as supply constraints and customer demand evolve.
- Track gross and operating margins against labor, component-cost and pricing-recovery pressures.
- Assess the effect of higher interest rates, revolver usage and debt maturities on interest expense and liquidity.
- Monitor customer and geographic concentration, particularly GEHC, APAC and Malaysia exposure, and the effects of China export controls.
- Verify the timing and magnitude of global minimum-tax impacts, the FY2024 tax-rate outlook, and any insurance recovery related to the Norway arbitration payment.